Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
CEO Walter Klemp discussed positive preliminary unblinded efficacy results from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial for Annamycin in R/R AML during a Virtual Investor segment. The company cautioned that the interim results are based on a small sample size and have not yet achieved statistical significance, requiring confirmation in the full study population.
Key figures
- Drug Name
- Annamycin
- Phase Of Trial
- Phase 2/3
- Patients enrolled
- 45
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.